Filing Flows › Health Care › Citius Pharmaceuticals (CTXR)
Citius Pharmaceuticals (CTXR) earnings and revenue breakdown
Latest: Q3 FY26 · 10-Q filed Aug 14, 2026 · Citius Pharmaceuticals (CTXR) Q3 FY26 earnings results →
Q3 FY26 798¢ of every $1 of revenue lost · operating margin -785.4%
Citius Pharmaceuticals made $1.5M in Q3 FY26. Operating margin -785.4%, net loss $11.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.5M in Q3 FY26, down 10% from the previous quarter.
Gross margin was 67.1%. Operating costs exceeded revenue by $11.7M, an operating margin of -785.4%. The quarter ended with a net loss of $11.9M, narrower than the previous quarter's $28.1M loss. Minority interests bore $3.1M of it: to shareholders the quarter was a loss of $8.9M.
Operating cash flow was −$8.7M. Non-cash charges added back $3.8M of share-based compensation. Working capital and other items used $569K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 FY26 | 10-Q | Aug 14, 2026 | $1.5M | — | -785.4% | −$11.9M | −$8.7M |
| Q2 FY26 | 10-Q | May 15, 2026 | $1.7M | — | n/m | −$28.1M | −$1.3M |
| Q1 FY26 | 10-Q | Feb 13, 2026 | $3.9M | — | -228.7% | −$9.4M | −$13.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products. Our goal generally is to achieve leading market positions by providing therapeutic products that address unmet medical needs yet have a lower development risk than usually is associated with new chemical entities. New formulations of previously approved drugs with substantial existing safety and efficacy data are a core focus. We seek to reduce development and clinical risks associated with drug development, yet still focus on innovative applications.
In its own words, from its 10-K, filed Dec 23, 2025.
Citius Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -785.4% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CTXR Citius Pharmaceuticals | Q3 FY26 | $1.5M | — | -785.4% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Citius Pharmaceuticals 10-Q on SEC EDGAR · CIK 1506251 · Pharmaceutical Preparations
13F: who owns CTXR and who is buying
More on CTXR
History
Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results